The U.S. is heading toward the 2026-2027 respiratory virus season without a functioning Advisory Committee on Immunization Practices (ACIP). That is no small disruption. ACIP has guided national policy on influenza vaccination since its first meeting in 1964, and since 2010 has maintained a universal annual recommendation for influenza vaccination for everyone 6 months and older. The committee has been central to the evidence-review process that translates vaccine science into clinical guidance, coverage obligations, purchasing decisions, and public communication.
Now that process has stalled. A federal district court in Massachusetts stayed the appointments of 13 ACIP members in American Academy of Pediatrics et al. v. Kennedy et al., following an unprecedented move by Health Secretary Robert F. Kennedy Jr. to fire all existing ACIP members. The committee has not been lawfully reconstituted nor convened. Kennedy has issued a charter that refocuses the responsibilities of the committee, but it’s little more than an attempt to rewrite the rules he has broken. No season-specific federal recommendation for influenza vaccination has yet been issued for the 2026-2027 season — and we don’t believe one is imminent.
But broad access to influenza vaccination is a public health necessity: the current off-season flu outbreak among military members offers an eye to what happens when immunization rates drop precipitously.
For providers, pharmacists, payers, and the millions of Americans who receive influenza vaccines each fall, the immediate question is simple: Will flu vaccines be available and covered this year? We believe the answer, for the 2026-2027 season, is yes.
A System Running on Workarounds
Even without ACIP, the existing system for influenza vaccine production, coverage, and delivery is resilient enough to hold together for now. But that resilience should not be confused with a functioning public health infrastructure. What will carry the country through this flu season is a collection of norms, professional society guidelines, legal backstops, and payer commitments.
In the absence of a federal recommendation, the clinical standard of care is increasingly being articulated by professional societies — and the consensus is uniform. The American Academy of Pediatrics continues to recommend annual influenza vaccination for all children beginning at 6 months of age. The American Academy of Family Physicians likewise published its own 2026 adult immunization schedule through an independent internal review process. Amid a backdrop of chaotic federal vaccine policy, providers will have a source of evidence-based guidance when recommending flu vaccines this fall.
Coverage Should Mostly Hold
The Affordable Care Act (ACA) requires commercial health plans to cover, without cost sharing, immunizations that have “in effect” a recommendation from ACIP. A rarely noticed structural reality is that the ACA’s implementing rules provide payers with a lengthy grace period to cover newly recommended vaccines. Given that make-up of antigen strains resets every year, this reveals that seasonal flu vaccine coverage has relied on payer good will.
That norm remains intact. America’s Health Insurance Plans recently renewed its members’ commitment to ongoing coverage of vaccines to ensure access and affordability for this respiratory virus season. Older adults, who are among the highest-priority populations for flu vaccination, are insulated from the current ACIP disruption because Medicare Part B coverage is statutorily required and does not depend on ACIP.
The Vaccines for Children program, which supplies federally purchased vaccines to Medicaid-eligible, uninsured, and underinsured children through age 18, must provide free doses of vaccines chosen by ACIP to states. Any ambiguity about whether 2026-2027 influenza vaccines will be covered by the program is resolved by Resolution No. 10/24-1, adopted by ACIP in October 2024. Because the resolution’s language is agnostic to any particular season or strain, it maintains operational legitimacy.
Medicaid coverage of influenza vaccines should also remain reasonably stable in the near term. The Inflation Reduction Act requires traditional Medicaid programs to cover, without cost sharing, FDA-approved adult vaccines recommended by ACIP. No implementing rules further define these requirements, though CMS guidance specifies that coverage must be consistent with ACIP recommendations. This opens the door to potential non-coverage and deserves the attention of states and Medicaid managed care organizations toward ensuring continuity of coverage for adults covered by Medicaid during the 2026-2027 influenza season.
Pharmacists Need Clarity in Some States
One practical access concern deserves particular attention: pharmacist vaccination authority. Many states authorize pharmacists to administer vaccines by referencing ACIP recommendations or CDC immunization schedules. In those states, the absence of a current-season federal recommendation could create a technical scope-of-practice question.
The Twelfth Amendment COVID Declaration Under the Public Readiness and Emergency Preparedness Act, extended through 2029, authorizes pharmacists in all 50 states to administer seasonal influenza vaccines to individuals ages 3 and older, preempting more restrictive state laws. However, this authority is limited “according to CDC’s/ACIP’s standard immunization schedule.”
HHS Could Fix This
The current situation is not inevitable. The HHS secretary retains authority to restore a functioning ACIP. He could appoint qualified new members. He could also designate ex officio members as voting members while a quorum is unavailable. Either step could allow the recommendation process to continue before the 2026-2027 respiratory season.
The plaintiffs in AAP v. Kennedy have made clear that their concern is not with merely maintaining long-standing, science-grounded vaccine recommendations. Their concern is the removal or downgrading of established recommendations without a credible scientific process.
The System Will Mostly Hold. That Is Not Good Enough.
The 2026-2027 influenza season will likely proceed without major coverage disruption. But contingencies do not make a system. Influenza is the best-case scenario for navigating a vaccine season without ACIP. It has a long history of annual guidance, a universal recommendation, broad payer support, mature manufacturing and distribution channels, and one of the deepest evidence bases in preventive medicine. If any vaccine can make it through a season on institutional memory and workarounds, it is flu.
But public health infrastructure should not depend on workarounds.
The longer the committee remains unable to function, the more likely today’s manageable uncertainty becomes tomorrow’s access barrier, coverage dispute, provider confusion, or decline in vaccine confidence.
